The review found no eligible studies for this question.
Temsirolimus + IFN‐α may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + IFN‐α showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + IFN‐α may leads to higher serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).
Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether everolimus + bevacizumab changes progression‐free survival (absolute effect size estimates based on… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
It is very uncertain whether everolimus + bevacizumab changes overall survival (absolute effect size estimates based on survival… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
Everolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (low certainty).
The review found no eligible studies for this question.
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
Pazopanib leads to lower progression‐free survival (absolute effect size estimates based on… compared with placebo (targeted agent versus placebo) (high certainty).
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).